We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Pergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals

News   Feb 11, 2013

 
Pergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals
 
 
Advertisement
 

RELATED ARTICLES

Biologic Therapy for Psoriasis May Also Have Applications in Heart Disease

News

Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research.

READ MORE

Tiny Antibody Component Neutralizes SARS-CoV-2 in Animal Models

News

Scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes SARS-CoV-2. This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drug, called Ab8, which holds potential as a therapeutic and prophylactic against SARS-CoV-2.

READ MORE

COVID-19 Phase 3 Trial To Evaluate REGN-COV2 Antibody Cocktail in UK

News

RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world’s largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron’s investigational anti-viral antibody cocktail known as REGN-COV2. The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE